In a randomized trial conducted in 27 intensive care units, we compared the clinical efficacy and safety of piperacillin-tazobactam (TAZ; 4 g/0.5 g q.i.d.) and of ceftazidime (CAZ; 1 g q.i.d.), both combined with amikacin (7.5 mg/kg b.i.d.), as therapy for ventilator-associated pneumonia (VAP; acquired after §48 hours of mechanical ventilation). VAP was diagnosed with use of protected samples and quantitative cultures, and outcome was assessed blindly from treatment. Of 204 patients suspected of having VAP and randomized to a treatment arm of the study, 127 (64%) had bacteriologically confirmed infections, of which 37% were polymicrobial and 32% involved Pseudomonas aeruginosa; 115 patients (51 TAZ and 64 CAZ recipients) remained evaluable as per protocol. Clinical/bacteriologic cure rates (TAZ vs. CAZ, 51% vs. 36%; 95% confidence interval of difference, 00.2% to 30.2%), and 28-day mortality rates (16% vs. 20%) were similar; however, fewer bacteriologic failures occurred with TAZ (33% vs. 51%; P Å .05). We conclude that the two regimens were of equivalent clinical efficacy in therapy for confirmed VAP.
Nosocomial pneumonia is associated with substantial morPiperacillin-tazobactam (TAZ) is a new broad-spectrum blactam combination that could cover most organisms responsibidity and mortality, especially for patients in intensive care units [1 -3] . While the severity of the underlying disease and ble for pneumonia acquired during mechanical ventilation [13] , and its use may be a promising approach to therapy for patients acute illness of the affected patients largely account for this poor outcome, improvements might be expected from progress having severe lower respiratory tract infection. The diagnosis of VAP, however, is fraught with difficulties in antimicrobial therapy. The epidemiology of pneumonia acquired during mechanical ventilation (the so-called ventilator- [14 -16] . Results of various antibiotic strategies investigated are difficult to assess because the population studied is often associated pneumonia, or VAP) has been described in several recent studies [2, 4 -7] . Most such infections are caused by ill-defined, combining patients with various presentations of lower respiratory tract infection, ranging from tracheobronchigram-negative bacilli, especially Pseudomonas species, and up to 40% of cases are caused by polymicrobial infection [5, 7] .
tis to severe pneumonia. The use of specific diagnostic techniques may allow more precise characterization of patients with Prior antimicrobial therapy is a risk factor both for pneumonia and for infections with more difficult-to-treat organisms, lead-VAP and more accurate selection of patients with VAP for inclusion in clinical trials [17 -19] . ing to poor response to therapy and a poor outcome [6, 8 -10] .
The current approach to empirical antimicrobial therapy for In this clinical trial we compared the outcome of therapy with TAZ or ceftazidime (CAZ), both in combination with VAP is use of a combination including a b-lactam drug and an aminoglycoside or one of the newer quinolones [11, 12] .
amikacin, in a well-defined group of intensive-care-unit patients having VAP, as confirmed by specific techniques using protected sampling procedures and quantitative cultures of respiratory tract secretions.
suspected of having VAP. The criteria for clinical suspicion aeruginosa and £8 mg/L and ú64 mg/L for all other species; ceftazidime, £4 mg/L and ú32 mg/L; and amikacin, £8 of VAP included all of the following: clinical signs of sepsis (new fever, increase in temperature over 38.2ЊC, or decrease mg/L and ú16 mg/L. These values are slightly (one dilution) more stringent than those recommended by the National Combelow 36.5ЊC; and increase in WBC count to ú10,000/mm 3 ); purulent tracheal aspirates; and a new infiltrate or otherwise mittee for Clinical Laboratory Standards. Drug regimens tested. Patients were randomized by center unexplained persistence or worsening of preexisting infiltrates on chest radiographs.
in blocks of four, according to a computer-generated randomization list, to receive a fixed combination of piperacillin and Patients were not eligible if they were diagnosed as having AIDS, a hematologic malignancy, or severe neutropenia (õ500 tazobactam (4 g of piperacillin and 500 mg of tazobactam q.i.d.) or ceftazidime (1 g q.i.d.), both in combination with polymorphonuclear cells/mm 3 ) or had a history of documented allergy to b-lactam antibiotics. Likewise, patients were not amikacin (15 mg/[kgrd] in two divided doses for patients with normal renal function). The b-lactam drug was expected to be eligible (1) if death was expected within 7 days of inclusion or a do-not-rescuscitate order had been written or (2) if they administered for 15 days, or up to 21 days for patients with difficult-to-treat organisms. Amikacin dosage was adapted to had a severity score (simplified acute physiology [SAPS II] score) [20] on inclusion higher than 50 and three or more renal function according to nomograms and trough serum levels. Amikacin was expected to be given for at least 10 days to organ failures [21] or a rapidly fatal underlying disease [22] . In addition, patients with suspected or documented tuberculosis, patients with infection involving P. aeruginosa and for at least 5 days to other patients. suspected or documented infection due to MRSA only, or a concomitant infection requiring other antimicrobial therapy (or that had necessitated the recent [õ48 hours previously] introAnalysis duction of antibiotics) were not eligible.
Microbiological diagnosis of VAP and secondary exclusions. Populations analyzed. For purposes of analysis, three populations were defined: (1) the overall evaluable population, includThe protocol required that one or several specific sampling techniques, followed by quantitative cultures, be used before ing all patients randomized and receiving at least one dose of the treatment regimen according to the protocol (this population inclusion of a patient in the study. Any one of the following three techniques was considered acceptable for obtaining respiwas analyzed for assessment of the safety of the two regimens); (2) patients with VAP, including all patients with microbiologiratory tract secretions: bronchoalveolar lavage [23] , protected specimen brush sampling via bronchoscopy [24] , or protected cally confirmed VAP; and (3) patients evaluable as ''per protocol,'' including all patients with microbiologically confirmed telescoping catheter sampling performed blindly or via fiberoptic bronchoscopy [25] .
VAP not due exclusively to MRSA and who had no major protocol violation. As only patients with confirmed pneumonia caused Although therapy was often initiated because of a clinical suspicion of VAP, only patients with microbiologically conby organisms potentially susceptible to the regimens used were targeted in this study, the latter population was used for the firmed VAP were subsequently retained in the primary efficacy analysis. The diagnosis of VAP was considered to be confirmed primary efficacy analysis. We also analyzed outcome in the subpopulation not having coinfection with MRSA. when the culture of at least one of the above three samples yielded bacteria at or above the required threshold for positivity Endpoints of study and definitions. All case report forms from all patients randomized were reviewed by a Clinical Evalfor the technique (i.e., 10 3 cfu/mL for protected specimen brush or telescoping catheter sampling and 10 4 cfu/mL for bronchoaluation Committee (CEC), which examined the adequacy of criteria for inclusion and diagnosis of VAP and the clinical veolar lavage). Patients whose samples were sterile or yielded bacteria in a concentration below the required threshold were and microbiological data relevant to outcome; the CEC members were blind to the treatment group assignment. The primary withdrawn from the study and secondarily excluded from the primary efficacy analysis. Patients whose samples yielded endpoint was clinical cure at 6 -8 days after the end of therapy, defined by the CEC as follows. MRSA only were also secondarily excluded. However, patients having infection caused by both MRSA and other organisms Cure was defined as complete or partial resolution of clinical signs and symptoms of pneumonia at the end of therapy, with susceptible to the assigned study drug regimen were given vancomycin in addition and were retained in the efficacy analysis.
no need for further antibiotic therapy during the 6 -8 days of follow-up. Failure was defined as the need for a change in Organisms recovered in cultures of respiratory tract secretions were identified in each hospital's clinical microbiology therapy during treatment or follow-up (including because of an adverse event); persistence, worsening, or relapse of clinical laboratory, and their susceptibility to the drugs used was tested with the disk-diffusion technique and breakpoints defined by symptoms of VAP, whether or not associated with microbiological failure (i.e., documented persistence, relapse, reinfection, the Antibiogram Committee of the French Society for Microbiology [26] . The MIC breakpoints used to define in vitro suscepor superinfection); and/or death possibly or probably related to infection. Death was considered possibly or probably related tibility and resistance, respectively, were as follows: piperacillin-tazobactam, £16 mg/L and ú64 mg/L for Pseudomonas to infection when it occurred during therapy or during the / 9c46$$fe05 01-14-98 11:04:04 cida UC: CID follow-up period and was not due to an intercurrent event McCabe and Jackson classification [22] , was present in 32% of patients. The primary causes for respiratory failure leading unrelated to the infection.
to mechanical ventilation [17] are listed in table 1. In addition Other endpoints included evaluation of microbiological outto respiratory failure, 17% of patients had one or more associcome, an analysis of mortality at end of therapy and at 28 days ated organ failure, according to criteria published by Knaus et postrandomization, and an evaluation of the safety of the two al. [21] ; 32 (25%) had severe sepsis; and 8 (6%) had septic regimens.
shock. There was no major difference in the clinical characterisStatistical analysis. Quantitative variables are given as tics of the 115 patients receiving TAZ or CAZ as per protocol, mean { SEM, unless specified otherwise. Differences between except for a predominance of males in the TAZ group (92% groups were compared with Student's t-test or Wilcoxon's vs. 77%; P Å .02) and a trend toward a higher frequency of rank-sum test where appropriate for quantitative variables and severe sepsis in CAZ patients (32% vs. 20%; P Å .10); howwith a x 2 test (with Fisher's correction where appropriate) for ever, the mean severity (SAPS II) score, which reflects the qualitative variables. Survival analysis used the log-rank test.
global severity of acute illness [20] , was similar on inclusion Comparison of the efficacy of the two regimens was made (37 vs. 37.5; P Å .8). under the hypothesis of equivalence of the two regimens, with
Microbiology of VAP. Each one of the three sampling techthe assumption that TAZ would not be less effective than CAZ niques required by the protocol was used for microbiological by ú15%; this analysis used the 95% confidence interval of confirmation of VAP episodes in approximately one-third of the difference of efficacy between the two drug regimens and cases; 147 of 163 samples obtained upon inclusion of the 127 a (unilateral) Dunnet-Gent test [27] .
patients with confirmed VAP yielded organisms in significant Assuming a secondary exclusion rate of 20% of randomized growth on quantitative cultures. Infection was monomicrobial in patients for lack of microbiological confirmation of VAP and 63% of patients; from 25% of patients two organisms and from a cure rate in the reference group of 60%, we planned to study 12% three or more organisms were recovered in significant a total of 160 patients with a clinical suspicion of VAP (we growth. In the per-protocol population (n Å 115), 170 organisms assumed a type one error of 5% and a type 2 error of 20%).
were recovered, with a similar distribution between the two treatBecause the exclusion rate proved to be higher during the study, ment groups (table 2) : gram-negative organisms accounted for this number was subsequently increased to a projected 232 68% of the cases of pneumonia, gram-positive for 12%, and a patients. Except for the analysis of equivalence between the combination of gram-positive and gram-negative for 20%. Four two regimens, all other tests were bilateral. Risk factors for VAP episodes (3.5%) were associated with bacteremia. P. aerugifailure of therapy in the per-protocol population and in the nosa accounted for 25% of all organisms and contributed to infecsubgroup with infection caused by susceptible organisms and tion in 32% of episodes; Staphylococcus aureus accounted for no coinfection with MRSA were subjected to a stepwise logistic 12% of organisms, including two MRSA isolates (2%). About regression analysis, including variables significant by univarione-fourth of episodes were caused by common respiratory pathoate analysis at a P level of £.15. Variables retained in the final gens such as Haemophilus influenzae or Streptococcus pneumomodel were selected at a P level of £.10.
niae, but only two patients had infection caused exclusively by members of the normal oropharyngeal flora. By disk-diffusion Results testing, 134 of 152 organisms tested (88%) and 122 of 151 (81%) were susceptible to TAZ and to CAZ, respectively, while 75.5% Populations analyzed. Of 204 patients randomized in the were susceptible to amikacin and only 66% to piperacillin. study, 197 received at least one dose of either drug regimen Drug dosage received (per-protocol analysis) . Patients tested according to the protocol and were evaluable with regard randomized to the TAZ group received a mean { SEM (range) to tolerance (98 TAZ and 99 CAZ recipients); 127 patients daily dosage of 14.7 { 0.3 (8 -16) g of piperacillin, for a (64.5%) had microbiologically confirmed VAP (58 TAZ and median duration of 15 (3 -24) days; patients randomized to the 69 CAZ recipients). From this group, 12 patients were excluded CAZ group received a mean daily dosage of 3.8 { 0.07 because of infection caused by MRSA only (n Å 5) or because (1 -6) g, for a median duration of 14 (2 -25) days. For patients of a major protocol violation (n Å 7), i.e., use of concomitant who remained in the study without early withdrawal (£4 days antimicrobial therapy not allowed by the protocol. Thus, 115 before the end of treatment), the median duration of treatment patients (51 TAZ and 64 CAZ recipients) with confirmed VAP was 15.5 and 16 days in the TAZ and CAZ groups, respectively. were evaluable as per-protocol, according to the CEC.
The mean amikacin daily dosages were 14.8 { 0.8 and 13.5 Clinical characteristics of patients with VAP upon inclusion { 0.6 mg/kg, respectively (P Å .4), for a median duration of (table 1) . In all patients with confirmed VAP (n Å 127), 9 (TAZ) and 8 (CAZ) days. infection was diagnosed after a mean duration of mechanical Outcome of Therapy ventilation of 11 days (median, 8 days), with two-thirds of cases (67%) occurring after 5 days (i.e., late-onset pneumonia);
Clinical outcome: all patients with VAP. At 6 -8 days post-76% of patients had received antibiotics prior to inclusion. A therapy, the overall success rate was 48% in the TAZ group and 33% in the CAZ group (OR, 2.14; 95% CI, 0.5% -29.5%). rapidly or ultimately fatal underlying disease, according to the / 9c46$$fe05 01-14-98 11:04:04 cida UC: CID Clinical outcome: per-protocol analysis. At the end-of-00.2% -30.2%), favoring TAZ recipients. Since the difference in efficacy rate did not exceed 15%, the two regimens were therapy assessment, 44% and 32% of TAZ and CAZ recipients, respectively, had no residual infiltrate on a chest radiograph found to be of equivalent clinical efficacy, according to the hypothesis tested. (P Å .2), and 50% and 38% were breathing spontaneously (P Å .2). At follow-up 6 -8 days post-therapy, 26 TAZ recipiAnalysis of treatment failures. According to the CEC, therapy failed for 25 (49%) and 40 (62.5%) of the TAZ and CAZ ents (51%) and 23 CAZ recipients (36%) had a successful clinical and bacteriologic outcome, as assessed by the CEC; recipients, respectively ( / 9c46$$fe05 01-14-98 11:04:04 cida UC: CID in 24 TAZ and 17 CAZ recipients. The frequency and distribution by site of all adverse events recorded were similar in both groups. Nine TAZ recipients and 10 CAZ recipients had adverse events judged as definitely, possibly, or probably related to the test drug (18% and 22%; P Å .68), including (in TAZ and CAZ recipients, respectively) hypereosinophilia (1 and 0), leukopenia (1 and 0), skin reactions (0 and 3), alteration in renal function (3 and 2), gastrointestinal tract disorder (1 and 0), and liver test abnormalities (4 and 4); treatment was interrupted because of a nonfatal adverse event in 3 and 4 patients, respectively. The overall 30-days-post-therapy mortality rate among all evaluable patients was 18.4% (18 of 98) in the TAZ group and 22.2% (22 of 99) in the CAZ group (P Å .55). awareness of the problem and the availability of several new antimicrobial agents [28] . In this study we chose to circumvent the problems associated with diagnostic criteria by using quanreceived (OR, 2.16; 95% CI, 1.18 -3.97; P Å .01), a shorter titative cultures of protected specimens to diagnose VAP. We delay of onset of pneumonia (OR, 0.96 per day; 95% CI, 0.92 -thus selected a population most probably having definite pul-1.0; P Å .10), and treatment with ceftazidime (OR, 1.99; 95% monary infection acquired during mechanical ventilation [10, CI, 0.88 -4.54; P Å .10). To further examine causes of failure 19] . In this well-defined population, we found that therapy with during therapy, we restricted this analysis to evaluable patients TAZ and amikacin was at least equivalent to the combination who had confirmed VAP caused by organisms found susceptiof CAZ and amikacin. However, both regimens were successful ble in vitro to the administered b-lactam drug and who were for £50% of patients with confirmed VAP, as assessed by the not shifted to another therapy because of primary resistance; independent CEC members, who were blind to the treatment patients coinfected with methicillin-resistant staphylococci regimen. (n Å 4) were excluded. In this subgroup of 99 patients, factors
Several factors related to the design and analysis of this associated with a poor outcome of therapy were again the study may account for this apparently unsatisfactory outcome, severity of underlying disease (OR, 2.68; 95% CI, 1.04 -6.88; in comparison with results of other studies in this field. First, P Å .041) and a shorter duration of mechanical ventilation clinical trials of antimicrobial therapy for lower respiratory before VAP (OR, 0.95; 95% CI, 0.89 -1.0; P Å .051); the tract infection have often combined patients having commutrend toward a higher risk of treatment failure with ceftazidime nity-acquired infection with patients having nosocomial infectherapy was confirmed (OR, 2.33; 95% CI,  tion. Even in trials restricted to patients with nosocomial infec-P Å .052).
tion, patients with pneumonia acquired during mechanical Mortality. In the per-protocol population (n Å 115), morventilation, such as ours, are usually combined with patients tality at 6 -8 days post-therapy was 14% in both groups, with 4 whose pneumonia was not acquired during such ventilation and 7 deaths attributed to infection in TAZ and CAZ recipients, and with patients not undergoing mechanical ventilation at all respectively; at 28 days postrandomization, mortality was 16% [28, 29] . Finally, in such trials, it is common to include patients (TAZ group) and 20% (CAZ group), and the probability of with ill-defined lower respiratory tract infections and to comsurvival at 28 days was similar (P Å .55) in the two groups bine patients having tracheobronchitis (likely associated with ( figure 1) . a better outcome) with patients having pneumonia. Most prior studies of nosocomial pneumonia have relied on tracheal aspiration to diagnose pneumonia in mechanically Safety ventilated patients. Although probably very sensitive, such sampling lacks specificity [19, 30] , and many patients included All 197 patients evaluable for safety received at least 2 days of therapy; 35% were treated for 2 -7 days only, whereas 28% in such studies may have had tracheobronchitis rather than pulmonary infection per se [18] ; often, no pathogen is isolated received therapy for ú15 days. Adverse events were recorded in 37 of 98 TAZ recipients (49 events) and 38 of 99 CAZ [31] , which makes outcome assessment difficult. We used protected samples cultured quantitatively to diagnose VAP, thus recipients (46 events); the adverse events were judged severe / 9c46$$fe05 01-14-98 11:04:04 cida UC: CID likely excluding patients with tracheobronchitis only. Accordfor confounding factors such as the severity of underlying disease and acute illness. It is noteworthy that a similar outcome ingly, more than one-third of patients eligible and randomized because of a strong clinical suspicion of pneumonia, based on of infection with P. aeruginosa was recorded in both treatment groups, with a 40% and 39% success rate, respectively, among the usual clinical criteria, were secondarily excluded because of the lack of microbiological confirmation of VAP.
TAZ and CAZ recipients; this suggests that both combination regimens were of similarly acceptable efficacy against P. aeruAlthough we excluded a priori patients with very severe acute illness or underlying disease, our inclusion criteria seginosa infection. One possible explanation for the higher rate of microbiologilected the population at highest risk of treatment failure and poor outcome [12] , and we believe our results closely reflect cal failures could be the relatively low ceftazidime dosage. Some authorities recommend that adult patients with infections the outcome of therapy for critically ill patients with VAP. A drawback of this approach is that an intention-to-treat analysis that are severe or due to difficult-to-treat organisms be given a higher ceftazidime dosage (i.e., 6g/d) than that used in this could not be used in the outcome evaluation, since most patients without microbiologically confirmed VAP had antibiotic therstudy (4 g/d), so that drug levels are maintained well above the MIC for organisms targeted; likewise, continuous adminisapy substituted or discontinued and were withdrawn from the study.
tration of ceftazidime has been suggested to improve efficacy and prevent emergence of resistance during therapy [34] . DeThe criteria for assessment of outcome of therapy were also stringent. The interpretation of these was based on recommenspite these theoretical grounds, it remains unproven that high ceftazidime dosages result in improved cure rates among nondations recently proposed by the Infectious Diseases Society of America [32] . For example, all cases in which new antibiotneutropenic patients. We used an intermediate dosing regimen of 1 g q.i.d. in patients with normal renal function, which should ics were introduced were classified as treatment failures, irrespective of the reason for their introduction. Likewise, we did provide sufficient 24-hour coverage for susceptible pathogens; besides, the potential value of higher dosages probably applies not exclude from the primary efficacy analysis those patients who were infected with organisms initially resistant to the allomore to monotherapy than to combined b-lactam/aminoglycoside therapy [31] . cated regimen and were switched to another regimen for this reason; although an intention-to-treat analysis was not used in At least one study found a similar outcome (with an 86% overall clinical response rate) in a randomized trial of therapy this study, such patients were categorized as treatment failures, because this study sought to examine the overall outcome of for severe lower respiratory tract infection in patients in an intensive care unit (82% of whom were undergoing mechanical therapy for patients with confirmed pneumonia due to organisms expected to be susceptible to the drug regimen tested.
ventilation) that compared a 3-g/d dosage of ceftazidime to a 6-g/d dosage [35] . Finally, in a recent trial comparing TAZ to In this randomized trial, the combination of TAZ and amikacin appeared at least as effective as the combination of CAZ CAZ (2 g t.i.d.), both administered with tobramycin or amikacin, for the treatment of hospital-acquired lower respiratory and amikacin; the former regimen actually tended to be superior, with an overall cure rate of 48% (vs. 33%) and a twicetract infection, Joshi et al. [29] found results similar to ours: the clinical outcome was better for patients receiving the former lower risk of treatment failure after multivariate analysis. As expected, treatment failures were associated, among other faccombination (74% vs. 50%; P õ .01), despite the fact that high doses of ceftazidime were administered. tors, with decreased susceptibility of the pathogens to the drug regimen received. The trend toward superior clinical efficacy Our results indicate that both regimens may be adequate empirical therapy for patients with suspected VAP when of TAZ and amikacin was reinforced after multivariate analysis, when the analysis was restricted to patients having infection MRSA is not a likely causative organism. We do not suggest that such therapy be used and maintained for all patients with caused only by organisms initially susceptible to the administered b-lactam drug and no coinfection with methicillin-resis-VAP, since unduly prolonged therapy with such broad-spectrum regimens may foster emergence of resistance and increase tant staphylococci. However, the relatively small number of patients retained in this analysis does not allow firm concluthe rate of superinfection. The antibiotic regimen should eventually be adapted to organisms subsequently identified and to sions in this regard, and this result would need confirmation in a larger study of appropriate design. their antibiotic susceptibility; in patients having pneumonia proven to be caused by organisms susceptible to narrowerTreatment failures among CAZ recipients appeared essentially associated with a higher incidence of persistence of initial spectrum drugs (especially those patients with early-onset pneumonia), as observed in about one-fourth of patients inorganisms or of reinfection and superinfection (table 3) . Most failures recorded in ceftazidime recipients were associated with cluded in this study, the initial empirical therapy should be replaced with such narrower-spectrum drugs. polymicrobial infection, and 45% of infections that responded poorly to CAZ were associated with P. aeruginosa. However, Our study also underscores the fact that, when defined with strict criteria, VAP entails a high risk of treatment failure, polymicrobial infection or infection with P. aeruginosa [28, 33] was not associated with treatment failure in the multivariate mostly due to superinfection or reinfection, even when combination therapy is used. It should be emphasized that the diaganalysis of risk factors for therapeutic failure, after correction / 9c46$$fe05 01-14-98 11:04:04 cida UC: CID
